Supernus, Inc. SUPN
Regular-session close
After hours · Nov 19, 4:00 PM ET
- YTD
- -20.99%
- 1 year
- -13.04%
5D -0.02 (-0.07%)
- Market cap
- 5.89B
- Revenue (ttm)
- 1.37B
- Profit margin
- 32.75%
- EPS (ttm)
- -0.76
- Shares out
- 207.72M
- Forward P/E
- 7.23
- YTD return
- -20.99%
- 1-year return
- -13.04%
- 50-day average
- 33.69
- 200-day average
- 35.37
- Volume
- 2.37M
- Avg volume
- 2.75M
- Open
- 29.11
- Previous close
- 28.96
- Day's range
- 28.32 – 29.37
- 52-week range
- 25.92 – 42.81
- Beta
- 1.13
- Analysts
- Strong Buy
- Price target
- 54.14 (+91.0%)
- Earnings date
- Feb 25, 2027
Key statistics
- Enterprise value
- 3.62B
- Price / sales
- 4.38
- Revenue growth
- 13.40%
- Free cash flow
- 227.12M
- Total cash
- 305.00M
- Total debt
- 501.00M
- Short % of float
- 9.72%
Fundamental scorecard
9 of 25 checks passed on SUPN’s reported financials
9of 25 checks passed
- Value 1 of 5
- Growth 4 of 5
- Profitability 2 of 5
- Financial health 2 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: strong buy
- Target (low)
- 45.00
- Target (mean)
- 54.14
- Target (high)
- 87.00
- Strong buy2
- Buy5
- Hold0
- Sell0
- Strong sell0
Next earnings
Feb 25, 2027
Expected Feb 25, 2027. Consensus EPS estimate 1.03.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 25, 2027 | Dec 30, 2026 | 0.87 | — | — | — |
| Oct 29, 2026 | Sep 30, 2026 | 1.06 | 1.32 | +0.26 | +24.53% |
| Aug 3, 2026 | Jun 30, 2026 | 0.869 | 1.15 | +0.28 | +32.34% |
| Apr 30, 2026 | Mar 31, 2026 | 0.64 | 0.96 | +0.32 | +50.00% |
| Feb 26, 2026 | Dec 31, 2025 | 0.65 | 0.82 | +0.17 | +26.15% |
| Oct 30, 2025 | Sep 30, 2025 | 0.38 | 0.72 | +0.34 | +89.47% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 9, 2026 | B of A Securities | init | — | Buy |
| Nov 4, 2026 | Cantor Fitzgerald | main | Overweight | Overweight |
| Oct 28, 2026 | Barclays | main | Overweight | Overweight |
| Aug 5, 2026 | Barclays | main | Overweight | Overweight |
| Jul 9, 2026 | Cantor Fitzgerald | main | Overweight | Overweight |
| Jun 18, 2026 | Barclays | init | — | Overweight |
About Supernus, Inc.
Supernus, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. Supernus, Inc. was formerly known as Indivior Pharmaceuticals, Inc. and changed its name Supernus, Inc. in November 2026. Supernus, Inc. was incorporated in 2014 and is headquartered in Rockville, Maryland.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- supernus.com
News
This Supernus Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday B of A Securities Initiates Coverage On Supernus with Buy Rating, Announces Price Target of $47
Piper Sandler Reinstates Overweight on Supernus, Announces $47 Price Target
Block To Rally Around 54%? Here Are 10 Top Analyst Forecasts For Wednesday Cantor Fitzgerald Maintains Overweight on Supernus, Raises Price Target to $87
12 Health Care Stocks Moving In Tuesday's Intraday Session
Supernus Pharmaceuticals Q3 2026 Earnings Call Transcript Supernus Pharmaceuticals Raises FY2026 Sales Guidance from $860.000M-$890.000M to $875.000M-$900.000M vs $877.738M Est
Supernus Pharmaceuticals Q3 EPS $0.35 Beats $0.02 Estimate, Sales $226.771M Beat $215.917M Estimate
MSG Rangers To Replace Arbor Realty Trust In The S&P SmallCap 600 Effective On October 27; Huron Consulting Group To Replace Supernus Pharmaceuticals In The S&P SmallCap 600 Effective Prior To The Opening Of Trading On Monday, November 2
Your note
Sign in to keep a note on SUPN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ANDERSON WOODROW D | Officer | Purchase | Aug 26, 2026 | 27,638 |
| BARRY PATRICK A | Officer | Stock Award(Grant) | Feb 9, 2026 | 31,380 |
| BURRIS JEFFREY W | Officer | Conversion of Exercise of derivative security | Mar 2, 2026 | 71,518 |
| CIAFFONI JOSEPH J | Chief Executive Officer | Conversion of Exercise of derivative security | Jun 21, 2026 | 790,330 |
| HEIDBREDER CHRISTIAN | Officer | Sale | Jul 9, 2026 | 209,337 |
| NINIVAGGI DANIEL A | Director | Stock Award(Grant) | May 12, 2026 | 27,163 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 15.79% | 18,634,083 | 539.64M | Sep 29, 2026 |
| Vanguard Portfolio Management LLC | 5.92% | 6,986,599 | 202.33M | Sep 29, 2026 |
| Millennium Management Llc | 5.32% | 6,282,351 | 181.94M | Sep 29, 2026 |
| Vanguard Capital Management LLC | 4.48% | 5,293,797 | 153.31M | Sep 29, 2026 |
| State Street Corporation | 4.27% | 5,037,536 | 145.89M | Sep 29, 2026 |
| Madison Avenue Partners, LP | 4.11% | 4,851,975 | 140.51M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 5.95% | 7,028,347 | 203.54M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.28% | 3,873,712 | 112.18M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.62% | 3,097,715 | 89.71M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.37% | 2,797,172 | 81.01M | Jun 29, 2026 |
| Capitol Series Trust-FullerThaler Behavioral Small-Cap Growth Fund | 1.82% | 2,152,304 | 62.33M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 1.36% | 1,609,803 | 46.62M | Jun 29, 2026 |
